B.C. Raimundo, A.J. Fry / Journal of Organometallic Chemistry 584 (1999) 230–234
233
up as above when bromosilane formation was com-
plete. The major product was isolated by preparative
GC and analyzed by GC-MS and 1H-NMR spec-
troscopy. Bromosilanes 6a and 7a have been described
previously 12. Structures of minor products were as-
signed from their mass spectra.
3.5. exo-7-Trimethylsilyl-endo-7-bromonorcarane (6a)
1H-NMR (CDCl3): l 0.03 (s, 9H), 1.0 (m, 2H), 1.23
(m, 2H), 1.4 (m, 2H), 1.5 (m, 2H), 2.0 (m, 2H). MS
m/e: 248, 246 [M+], 206, 204, 139, 137 (100), 93.
Scheme 3.
3.1. General procedure for synthesis of
dibromocyclopropanes
3.6. endo-7-Trimethylsilyl-exo-7-bromonorcarane (7a)
A slurry of alkene and three to five equivalents of
potassium t-butoxide was cooled in an ice bath. Three
equivalents of bromoform were added drop-wise and
the mixture was allowed to stir; total addition plus
stirring time ranged from 4 to 7 h. Distilled water was
then added. The aqueous layer was extracted with
hexane; the organic layer was washed with water. The
combined organic layers were dried over MgSO4, sol-
vent was evaporated, and the dibromide purified by
fractional distillation. Dibromocyclopropanes 4a [12],
4b [35], 4d [36] and 4e [20] are known compounds.
1H-NMR (CDCl3): l 0.25 (s, 9H), 1.2 (m, 4H), 1.45
(m, 2H), 1.7 (m, 2H), 1.9 (m, 2H). MS m/e: 248, 246
[M+], 233, 231, 139, 137 (100), 93.
3.7. exo-7-Trimethylsilyl-endo-7-bromo-1-
methylnorcarane (6b)
1H-NMR (CDCl3): l 0.17 (s, 9H), 0.96 (dd, 1H), 1.2
(s, 3H), 1.26 (m, 2H), 1.46 (m, 3H), 1.66 (m, 1H), 1.84
(m, 1H), 2.00 (m, 1H). MS m/e: 262, 260 [M+], 139,
137, 107, 93, 91, 73 (100).
3.2. 1-Ethyl-7,7-dibromonorcarane (4c)
3.8. exo-7-Trimethylsilyl-endo-7-bromo-1-
ethylnorcarane (6c)
1
B.p. 71–73°C/0.2 mm. H-NMR (CDCl3): l 1.08 (t,
3H), 1.46 (dd, 1H), and 1.16–2.01 (m, 10H). MS m/e:
284, 282, 280 [M+], 255, 253, 251 (100), 203, 201, 121.
1H-NMR (CDCl3): l 0.2 (s, 9H), 0.94 (t, 3H), 1.14–
1.6 (m, 9H), 1.76 (t, 1H), 2.0 (m, 1H). MS m/e: 276,
274 [M+], 248, 246, 139, 137, 107, 93, 91, 73 (100).
3.3. 1-Phenyl-7,7-dibromonorcarane20 (4e)
3.9. exo-7-Trimethylsilyl-endo-7-bromo-1-
isopropylnorcarane (6d)
Spectral data appear not to have been reported in the
literature for this compound. B.p. 118°C/0.1 mm. H-
1
NMR (CDCl3): l 1.35 (m, 4H), 1.55 (m, 2H), 1.8 (m,
1H), 2.1–2.3 (m, 2H), 7.3 (m, 4 H), and 7.4 (t, 1H). MS
m/e: 251 (63), 249 (63) [M+ −Br], 169 (100), 141 (81),
91 (45).
1H-NMR (CDCl3): l 0.22 (s, 9H), 0.92 (dd, 1H), 0.96
(d, 3H), 0.97 (d, 3H), 1.2 (m, 2H), 1.4–1.6 (m, 5H),
1.89 (m, 1H), 2.02 (m, 1H). MS m/e: 290, 288 [M+],
247, 245, 139, 137, 93, 91, 73 (100).
3.4. Representati6e procedure for sonochemical
reducti6e silylation
3.10. exo-7-Triethylsilyl-endo-7-bromo-norcarane (10a)
1H-NMR (CDCl3): l 0.6 (q, 6H), 0.97 (t, 9H), 1.05
(dd, 2H), 1.26 (m, 2H), 1.41 (m, 2H), 1.55 (m, 2H), 2.0
(m, 2H). MS m/e: 290, 288 [M+], 233, 231, 167 (100),
165 (100), 139, 137, 93, 91.
Dry THF (25 ml), magnesium powder (0.100 g, 4.1
mmol) dibromide 4a (0.97 g, 3.8 mmol), and chlorosi-
lane 5a (0.51 g, 4.7 mmol) were added to a large
flame-dried test tube which was then sealed with a
rubber septum and flushed with nitrogen. The opaque
gray suspension was immersed in a water-filled Bran-
sonic 2200 ultrasonic bath and sonicated for 3 h, after
which it was a clear yellow solution. Samples were
removed periodically, quenched with aqueous
NaHCO3, extracted with ether and dried. The ether
extract was analyzed by GC. The mixture was worked
3.11. exo-7-Triethylsilyl-endo-7-bromo-1-
methylnorcarane (10b)
1H-NMR (CDCl3): l 0.67 (q, 6H), 0.97 (t, 9H),1.16
(s, 3H), 1.0–2.3 (m, 9 H). MS m/e: 275, 273, 167, 165
(100), 139, 137, 107, 93, 79.